Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms CPD-141 |
Target |
Mechanism TrkA antagonists(Nerve growth factor receptor Trk-A antagonists), TrkB inhibitors(Neurotrophic tyrosine kinase receptor type 2 inhibitors), TrkC inhibitors(Neurotrophic tyrosine kinase receptor type 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC54H61F2N9O11 |
InChIKeyWZZQEDKZQHBYFG-UHFFFAOYSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 18 May 2020 |